NO20054164L - Immunoglobulinformulering og fremgangsmåte for fremstilling derav - Google Patents

Immunoglobulinformulering og fremgangsmåte for fremstilling derav

Info

Publication number
NO20054164L
NO20054164L NO20054164A NO20054164A NO20054164L NO 20054164 L NO20054164 L NO 20054164L NO 20054164 A NO20054164 A NO 20054164A NO 20054164 A NO20054164 A NO 20054164A NO 20054164 L NO20054164 L NO 20054164L
Authority
NO
Norway
Prior art keywords
preparation
polysorbate
immunoglobulin formulation
antibody
formulation
Prior art date
Application number
NO20054164A
Other languages
English (en)
Other versions
NO346070B1 (no
Inventor
Christopher Phillips
David Burke
Shaun E Buckley
Sherwood Russ Lehrman
Barbara Horsey O'connor
James Calloway
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054164(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20054164L publication Critical patent/NO20054164L/no
Publication of NO346070B1 publication Critical patent/NO346070B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En stabil vanlig farmasøytisk formulering som omfatter en terapeutisk effektiv mengde av et antistoff, polysorbat 80, en buffer som inhiberer polysorbatoksidering, bhr beskrevet sammen med fremgangsmåte for fremstilling av preparatet. Også beskrevet er formuleringer med høye antistoff-konsenttasjoner som opprettholdes i fastsatte volumer og som kan bh benyttet på pasienter med variabel vekt.
NO20054164A 2003-02-10 2004-02-09 Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav. NO346070B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
PCT/US2004/003873 WO2004071439A2 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof

Publications (2)

Publication Number Publication Date
NO20054164L true NO20054164L (no) 2005-09-07
NO346070B1 NO346070B1 (no) 2022-01-31

Family

ID=32869424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054164A NO346070B1 (no) 2003-02-10 2004-02-09 Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.

Country Status (29)

Country Link
US (7) US20050053598A1 (no)
EP (4) EP3417875B1 (no)
JP (3) JP4728948B2 (no)
KR (1) KR20050110628A (no)
CN (2) CN103040732B (no)
AR (1) AR043144A1 (no)
AU (2) AU2004210679A1 (no)
CA (1) CA2515444C (no)
CL (1) CL2004000224A1 (no)
CY (2) CY1120574T1 (no)
DK (2) DK3417875T3 (no)
ES (1) ES2819011T3 (no)
HK (1) HK1182021A1 (no)
HU (1) HUE051878T2 (no)
IL (1) IL170008A (no)
MX (1) MXPA05008409A (no)
MY (1) MY162623A (no)
NO (1) NO346070B1 (no)
PE (1) PE20050190A1 (no)
PT (2) PT2236154T (no)
RU (1) RU2358763C2 (no)
SI (2) SI3417875T1 (no)
SK (1) SK50672005A3 (no)
TR (1) TR201808801T4 (no)
TW (1) TWI367766B (no)
UA (1) UA82685C2 (no)
UY (1) UY28184A1 (no)
WO (1) WO2004071439A2 (no)
ZA (1) ZA200506159B (no)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP3417875B1 (en) * 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US10765747B2 (en) * 2004-04-02 2020-09-08 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
MX2007010970A (es) * 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-molecula de adhesion celular adresina de mucosas.
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP2354162A1 (en) * 2005-09-12 2011-08-10 Novimmune SA Anti-CD3 antibody formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
WO2007076524A2 (en) * 2005-12-29 2007-07-05 Centocor, Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP2359834B1 (en) 2006-03-15 2016-11-09 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR20090060453A (ko) * 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
CA2677831A1 (fr) * 2007-02-12 2008-08-21 Lassaad Boujbel Le sucralose solution sterile sans conservateurs
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
US8633034B2 (en) * 2007-06-25 2014-01-21 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2009129226A1 (en) 2008-04-15 2009-10-22 Talecris Biotherapeutics, Inc. Two-stage ultrafiltration/diafiltration
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
CA2748365C (en) * 2008-12-29 2015-02-17 Samyang Corporation Pharmaceutical composition of lyophilized formulation and preparation method of the same
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
WO2010121141A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
DK2477603T3 (en) * 2009-09-17 2016-06-13 Baxalta Inc STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP3216462A3 (en) * 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
SI2558499T1 (sl) 2010-04-16 2017-08-31 Biogen MA Inc., Protitelesa proti VLA-4
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
HUE033071T2 (hu) 2010-06-04 2017-11-28 Wyeth Llc Vakcinakészítmények
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US8795658B2 (en) * 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2800066T3 (es) 2010-10-25 2020-12-23 Biogen Ma Inc Procedimientos para determinar diferencias en la actividad de la integrina alfa-4 mediante correlación de diferencias en niveles de sVCAM y/o sMAdCAM
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
AU2012260807B2 (en) * 2011-05-26 2016-05-12 Glaxosmithkline Biologicals Sa Inactivated Dengue virus vaccine
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
SG11201403792TA (en) * 2012-01-23 2014-10-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
CA3123252C (en) * 2012-03-26 2023-08-22 Sanofi Stable anti-cxcr5 igg4 antibody formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834358A4 (en) 2012-04-02 2016-03-09 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102372245B1 (ko) 2013-11-21 2022-03-08 젠맵 에이/에스 항체-약물 접합체 동결건조 제제
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TWI752912B (zh) * 2015-07-17 2022-01-21 美商寇西勒斯生物科技股份有限公司 那他珠單抗的穩定水性調配物
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3402465B1 (en) 2016-01-13 2024-03-13 Genmab A/S Formulation for antibody and drug conjugate thereof
RU2732109C2 (ru) 2016-02-10 2020-09-11 Бектон Дикинсон Франс Способ оценки стабильности композиции на основе белка
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
EA202091382A1 (ru) 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019173767A1 (en) 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
AU2019253070A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Antibody formulation
SG11202009872YA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Stable antibody formulation
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
JP2020002130A (ja) 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
EP3883607A4 (en) 2018-11-20 2022-08-17 Janssen Biotech, Inc. SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
EP3903815A4 (en) * 2018-12-24 2022-09-28 Grand Theravac Life Science (Nanjing) Co., Ltd. PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEPATITIS B, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
KR20220019018A (ko) * 2019-06-07 2022-02-15 아르제넥스 비브이비에이 피하 투여에 적합한 FcRn 억제제의 약학적 제형
MX2021015213A (es) * 2019-06-11 2022-01-18 Macrogenics Inc Formulaciones farmaceuticas de diacuerpos biespecificos y uso de las mismas.
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
AU2021207632A1 (en) * 2020-01-13 2022-07-07 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
CN115023276A (zh) * 2020-01-29 2022-09-06 默沙东有限公司 从抗-lag3抗体生产中分离宿主细胞脂肪酶的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508132C3 (de) * 1974-03-08 1980-10-16 Teijin Ltd., Osaka (Japan) Verfahren zur Herstellung von Humanimmunglobulin-Derivaten und parenteral applizierbare Lösung hiervon
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
TR200501367T2 (tr) 1999-03-25 2005-09-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
WO2002060415A1 (de) * 2001-01-31 2002-08-08 Röhm GmbH & Co. KG Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20050118163A1 (en) * 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP3417875B1 (en) * 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
WO2004100984A1 (en) 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
CN1946407B (zh) 2004-02-06 2011-10-05 伊兰药品公司 治疗肿瘤和转移性疾病的药物
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos

Also Published As

Publication number Publication date
PT3417875T (pt) 2020-08-24
SK50672005A3 (sk) 2006-03-02
US20150044206A1 (en) 2015-02-12
US20120328614A1 (en) 2012-12-27
AU2010202254B2 (en) 2012-02-23
KR20050110628A (ko) 2005-11-23
HUE051878T2 (hu) 2021-03-29
UY28184A1 (es) 2004-09-30
DK3417875T3 (da) 2020-08-31
CN1771053B (zh) 2012-10-03
US10954303B2 (en) 2021-03-23
EP1592440A2 (en) 2005-11-09
JP2014028831A (ja) 2014-02-13
CA2515444C (en) 2014-04-01
JP4728948B2 (ja) 2011-07-20
SI2236154T1 (en) 2018-08-31
US8815236B2 (en) 2014-08-26
CN103040732B (zh) 2015-04-01
CA2515444A1 (en) 2004-08-26
CY1120574T1 (el) 2019-07-10
JP2006517233A (ja) 2006-07-20
US8900577B2 (en) 2014-12-02
US20050053598A1 (en) 2005-03-10
US20100021461A1 (en) 2010-01-28
MY162623A (en) 2017-06-30
SI3417875T1 (sl) 2021-01-29
EP2236154B1 (en) 2018-05-30
CN1771053A (zh) 2006-05-10
HK1182021A1 (en) 2013-11-22
TW200505478A (en) 2005-02-16
WO2004071439A3 (en) 2005-07-07
AR043144A1 (es) 2005-07-20
RU2358763C2 (ru) 2009-06-20
PE20050190A1 (es) 2005-03-21
CL2004000224A1 (es) 2005-01-21
ES2819011T3 (es) 2021-04-14
EP1592440A4 (en) 2007-07-11
IL170008A (en) 2015-05-31
AU2004210679A1 (en) 2004-08-26
EP2236154A1 (en) 2010-10-06
CN103040732A (zh) 2013-04-17
EP3417875A1 (en) 2018-12-26
RU2005128280A (ru) 2006-06-10
UA82685C2 (uk) 2008-05-12
US20210292419A1 (en) 2021-09-23
NO346070B1 (no) 2022-01-31
US20130071386A1 (en) 2013-03-21
CY1123667T1 (el) 2022-03-24
AU2010202254A1 (en) 2010-06-24
WO2004071439A2 (en) 2004-08-26
JP2011088913A (ja) 2011-05-06
EP3777880A1 (en) 2021-02-17
TWI367766B (en) 2012-07-11
ZA200506159B (en) 2006-10-25
DK2236154T3 (en) 2018-06-25
EP3417875B1 (en) 2020-06-17
PT2236154T (pt) 2018-06-26
US20180194843A1 (en) 2018-07-12
MXPA05008409A (es) 2005-10-05
TR201808801T4 (tr) 2018-07-23
US8349321B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
NO20054164L (no) Immunoglobulinformulering og fremgangsmåte for fremstilling derav
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
NZ592918A (en) Antibody formulation comprising an IL-1beta antibody and a buffer
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DK1651270T3 (da) Medikamenter til inhalation omfattende betamimetika og et anticholinergikum
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
NO20062668L (no) Orale formuleringer av desoxypeganin og anvendelser derav
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
DE602004017164D1 (de) Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
ATE262898T1 (de) Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
ITFO20020011A0 (it) Strumento di cannula vaginale atto ad eseguire irrigazioni vaginali con successiva somministrazione in vagina di principi attivi in formulaz
NO20065853L (no) Hydrogelinterferonformuleringer
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN IDEC MA INC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN MA INC., US